Comparative Pharmacology
Head-to-head clinical analysis: ALA CORT versus CLOBETASOL PROPIONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA CORT versus CLOBETASOL PROPIONATE.
ALA-CORT vs CLOBETASOL PROPIONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing prostaglandin and leukotriene synthesis, and exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.
Corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines and suppression of immune response via modulation of gene expression.
Topical: Apply a thin film to affected area 3-4 times daily. Dosage strength: 0.5% cream or ointment.
Apply topically as a thin film to affected areas once to twice daily. Maximum 50 g/week. Treatment duration not to exceed 2 consecutive weeks.
None Documented
None Documented
Clinical Note
moderateClobetasol propionate + Gatifloxacin
"The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Gatifloxacin."
Clinical Note
moderateClobetasol propionate + Rosoxacin
"The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Rosoxacin."
Clinical Note
moderateClobetasol propionate + Levofloxacin
"The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Levofloxacin."
Clinical Note
moderateTerminal elimination half-life: 1–2 hours for hydrocortisone (active component), prolonged in liver disease or with concurrent CYP3A4 inhibitors.
Terminal elimination half-life is approximately 2-3 hours after topical application. However, due to prolonged cutaneous retention, clinical effects may persist beyond systemic elimination.
Primarily hepatic metabolism (approximately 95%) followed by renal excretion of inactive metabolites (<5% unchanged). Biliary/fecal excretion is negligible.
Primarily fecal (biliary) with minimal renal excretion. Less than 5% of a topical dose is recovered in urine as metabolites; the majority is eliminated via feces after hepatic metabolism.
Category C
Category A/B
Topical Corticosteroid
Topical Corticosteroid
Clobetasol propionate + Trovafloxacin
"The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Trovafloxacin."